Stoke Therapeutics Files 8-K/A Amendment
Ticker: STOK · Form: 8-K/A · Filed: Sep 18, 2025 · CIK: 1623526
| Field | Detail |
|---|---|
| Company | Stoke Therapeutics, Inc. (STOK) |
| Form Type | 8-K/A |
| Filed Date | Sep 18, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, corporate-governance, filing
TL;DR
Stoke Therapeutics filed an amendment to a shareholder vote report, no major news.
AI Summary
Stoke Therapeutics, Inc. filed an 8-K/A on September 18, 2025, to amend a previous filing regarding the submission of matters to a vote of security holders. The original event date was June 3, 2025. The company, incorporated in Delaware, is located at 45 Wiggins Avenue, Bedford, MA.
Why It Matters
This filing is an amendment to a previous report concerning shareholder votes, indicating a procedural update or correction to corporate governance matters.
Risk Assessment
Risk Level: low — This is a procedural amendment to a previous filing and does not appear to contain new material information or significant business changes.
Key Players & Entities
- Stoke Therapeutics, Inc. (company) — Registrant
- 45 Wiggins Avenue, Bedford, MA (location) — Principal Executive Offices
- June 3, 2025 (date) — Earliest event reported
- September 18, 2025 (date) — Filing date
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing serves as an amendment to a previous report concerning the submission of matters to a vote of security holders.
When was the earliest event reported in this filing?
The earliest event reported was on June 3, 2025.
What is the filing date of this 8-K/A?
This 8-K/A was filed as of September 18, 2025.
What is the principal business address of Stoke Therapeutics, Inc.?
The principal executive offices are located at 45 Wiggins Ave, Bedford, Massachusetts 01730.
What is the SIC code for Stoke Therapeutics, Inc.?
The Standard Industrial Classification code is 2834, Pharmaceutical Preparations.
Filing Stats: 580 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2025-09-18 16:07:59
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Glo
Filing Documents
- d798098d8ka.htm (8-K/A) — 24KB
- 0001193125-25-207401.txt ( ) — 137KB
- stok-20250603.xsd (EX-101.SCH) — 3KB
- stok-20250603_lab.xml (EX-101.LAB) — 18KB
- stok-20250603_pre.xml (EX-101.PRE) — 11KB
- d798098d8ka_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STOKE THERAPEUTICS, INC. Date: September 18, 2025 By: /s/ Thomas E. Leggett Thomas E. Leggett Chief Financial Officer